Comparable stake leader
BlackRock, Inc.
SEC ownership of Nurix Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001549595.
Disclosed value leader
BlackRock, Inc.
Comparable rows
12/50
Latest evidence
16 Sep 2026
- Public ticker
- NRIX on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
12 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
16 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001549595
- Issuer location
- Brisbane, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Nurix Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
12/50
Latest evidence
16 Sep 2026
13F
13D/G
3/4/5
Lead comparable stake: 8.2%
38 rows are not safely comparable across share classes.
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 8.2%.
12 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
8.2%
Redmile Group, LLC
8.1%
Vestal Point Capital, LP
7.8%
Deep Track Capital, LP
7.4%
BAKER BROS. ADVISORS LP
7.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
8.2%
Reported 13D/G
· 31 Mar 2025
|
$212,768,666
8,770,349 shares
|
— | 30 Jun 2026 |
| Redmile Group, LLC |
13D/G
13F
Company
|
8.1%
Reported 13D/G
· 30 Jun 2026
|
$210,510,676
8,782,256 shares
|
-$45,879,970 | 30 Jun 2026 |
| Vestal Point Capital, LP |
13F
13D/G
Company
|
7.8%
Reported 13D/G
· 30 Jun 2026
|
$195,293,000
8,050,000 shares
|
— | 30 Jun 2026 |
| Deep Track Capital, LP |
13F
13D/G
Company
|
7.4%
Reported 13D/G
· 30 Jun 2026
|
$187,686,398
7,736,455 shares
|
— | 30 Jun 2026 |
| BAKER BROS. ADVISORS LP |
13D/G
13F
Company
|
7.2%
Reported 13D/G
· 31 Dec 2025
|
$138,364,566
7,527,996 shares
|
$0 | 31 Dec 2025 |
| Rubric Capital Management LP |
13F
13D/G
Company
|
7%
Reported 13D/G
· 30 Jun 2026
|
$175,345,894
7,227,778 shares
|
— | 30 Jun 2026 |
| FMR LLC |
13F
13D/G
Company
|
5.4%
Reported 13D/G
· 31 Mar 2026
|
$133,071,325
5,485,215 shares
|
— | 30 Jun 2026 |
| PERCEPTIVE ADVISORS LLC |
13D/G
13F
Company
|
5.3%
Reported 13D/G
· 16 Sep 2026
|
$149,765,814
5,536,629 shares
|
$0 | 16 Sep 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$5,229,694.
Buys
$0
Insiders: 0
Sells
$5,229,694
Insiders: 4
Net
-$5,229,694
Shares: -273,113
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 273,113
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 77,416 | $0 | $1,838,852 | -$1,838,852 |
| 3-6 | 0 | 89,898 | $0 | $1,691,685 | -$1,691,685 |
| 6-9 | 0 | 43,534 | $0 | $702,957 | -$702,957 |
| 9-12 | 0 | 62,265 | $0 | $996,200 | -$996,200 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 20 reporting-owner rows connected to Nurix Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
20
Largest Forms 3/4/5 holder
Third Rock Ventures III, L.P.
Net 12M change
-$5,229,694
Latest report
15 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Third Rock Ventures III, L.P. | 10%+ Owner | $35,104,359 | Mixed | 06 May 2021 | ||
| COLUMN GROUP L P | 10%+ Owner | $14,431,862 | Mixed | 07 May 2021 | ||
| Gwenn Hansen | Chief Scientific Officer | $3,633,139 | -$667,205 | -16% | Mixed | 15 Oct 2026 |
| Hans van Houte | Chief Financial Officer | $1,692,451 | -$635,333 | -27% | Mixed | 04 Aug 2026 |
| Pierre Beaurang | Chief Business Officer | $1,210,335 | Mixed | 10 Aug 2021 | ||
| Christine Ring | Chief Legal Officer | $913,680 | -$3,398,628 | -79% | Mixed | 02 Oct 2026 |
| Julia P. Gregory | Director | $251,590 | -$528,528 | -68% | Filing P/S | 14 Oct 2026 |
| Stefani Wolff | EVP and COO | $145,701 | Mixed | 30 Apr 2023 | ||
| Lori Anne Kunkel | Director | $0 | Mixed | 19 May 2025 | ||
| Judith A. Reinsdorf | Director | Mixed | 15 May 2026 | |||
| Leon Chen | Director | Mixed | 06 May 2021 | |||
| Edward C. Saltzman | Director | Mixed | 15 May 2026 | |||
| Roy D. Baynes | Director | Mixed | 15 May 2026 | |||
| Clay B. Siegall | Director | Mixed | 05 May 2022 | |||
| Jeffrey K. Tong | Director, 10%+ Owner | Mixed | 06 May 2021 | |||
| Roger D. Dansey | Director | Mixed | 15 May 2026 | |||
| Anil Kapur | Director | Mixed | 15 May 2026 | |||
| Paul M. Silva | Director | Mixed | 15 May 2026 | |||
| Arthur T. Sands | President, CEO, Director | Mixed | 10 Feb 2026 | |||
| David L. Lacey | Director | Mixed | 15 May 2026 |
Recent insider transactions for Nurix Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Gwenn Hansen | NRIX | Common Stock | Sale | -1.22% | $36,300 | $25.00 | -1,452 | 117,227 | 15 Oct 2026 | Direct |
| Gwenn Hansen | NRIX | Common Stock | Options Exercise | 1.24% | 1,452 | 118,679 | 15 Oct 2026 | Direct | ||
| Gwenn Hansen | NRIX | Employee Stock Option (right to buy) | Options Exercise | -2.39% | -1,452 | 59,406 | 15 Oct 2026 | Direct | ||
| Julia P. Gregory | NRIX | Common Stock | Sale | -67.8% | $528,528 | $23.40 | -22,583 | 10,750 | 14 Oct 2026 | Direct |
| Julia P. Gregory | NRIX | Common Stock | Options Exercise | 210.1% | 22,583 | 33,333 | 14 Oct 2026 | Direct | ||
| Julia P. Gregory | NRIX | Director Stock Option (right to buy) | Options Exercise | -100% | -22,583 | 0 | 14 Oct 2026 | Direct | ||
| Christine Ring | NRIX | Common Stock | Sale | -38.8% | $134,149 | $23.19 | -5,786 | 9,110 | 02 Oct 2026 | Direct |
| Christine Ring | NRIX | Common Stock | Options Exercise | 63.5% | 5,786 | 14,896 | 02 Oct 2026 | Direct | ||
| Christine Ring | NRIX | Employee Stock Option (right to buy) | Options Exercise | -4.94% | -5,786 | 111,251 | 02 Oct 2026 | Direct | ||
| Christine Ring | NRIX | Common Stock | Sale | -38.8% | $149,072 | $25.76 | -5,787 | 9,110 | 02 Sep 2026 | Direct |
| Christine Ring | NRIX | Common Stock | Options Exercise | 63.5% | 5,787 | 14,897 | 02 Sep 2026 | Direct | ||
| Christine Ring | NRIX | Employee Stock Option (right to buy) | Options Exercise | -4.71% | -5,787 | 117,037 | 02 Sep 2026 | Direct | ||
| Gwenn Hansen | NRIX | Common Stock | Sale | -1.22% | $36,982 | $25.47 | -1,452 | 117,227 | 01 Sep 2026 | Direct |
| Gwenn Hansen | NRIX | Common Stock | Options Exercise | 1.24% | 1,452 | 118,679 | 01 Sep 2026 | Direct | ||
| Gwenn Hansen | NRIX | Employee Stock Option (right to buy) | Options Exercise | -2.33% | -1,452 | 60,858 | 01 Sep 2026 | Direct | ||
| Gwenn Hansen | NRIX | Common Stock | Sale | -3.58% | $108,900 | $25.00 | -4,356 | 117,227 | 05 Aug 2026 | Direct |
| Gwenn Hansen | NRIX | Common Stock | Options Exercise | 3.72% | 4,356 | 121,583 | 05 Aug 2026 | Direct | ||
| Gwenn Hansen | NRIX | Employee Stock Option (right to buy) | Options Exercise | -6.53% | -4,356 | 62,310 | 05 Aug 2026 | Direct | ||
| Gwenn Hansen | NRIX | Common Stock | Sale | -3.39% | $100,142 | $24.36 | -4,111 | 117,227 | 04 Aug 2026 | Direct |
| Hans van Houte | NRIX | Common Stock | Sale | -10.6% | $115,989 | $24.36 | -4,761 | 40,166 | 04 Aug 2026 | Direct |
| Christine Ring | NRIX | Common Stock | Sale | -64.6% | $382,358 | $23.05 | -16,589 | 9,110 | 03 Aug 2026 | Direct |
| Christine Ring | NRIX | Common Stock | Options Exercise | 29.1% | 5,787 | 25,699 | 03 Aug 2026 | Direct | ||
| Christine Ring | NRIX | Employee Stock Option (right to buy) | Options Exercise | -4.5% | -5,787 | 122,824 | 03 Aug 2026 | Direct | ||
| Hans van Houte | NRIX | Common Stock | Sale | -5.96% | $66,524 | $23.38 | -2,845 | 44,927 | 30 Jul 2026 | Direct |
| Hans van Houte | NRIX | Common Stock | Options Exercise | 27.1% | 10,180 | 47,772 | 30 Jul 2026 | Direct | ||
| Hans van Houte | NRIX | Restricted Stock Units | Options Exercise | -47.5% | -10,180 | 11,250 | 30 Jul 2026 | Direct | ||
| Christine Ring | NRIX | Common Stock | Sale | -16.2% | $89,954 | $23.38 | -3,847 | 19,912 | 30 Jul 2026 | Direct |
| Christine Ring | NRIX | Common Stock | Options Exercise | 75% | 10,180 | 23,759 | 30 Jul 2026 | Direct | ||
| Christine Ring | NRIX | Restricted Stock Units | Options Exercise | -47.5% | -10,180 | 11,250 | 30 Jul 2026 | Direct | ||
| Gwenn Hansen | NRIX | Common Stock | Sale | -3.07% | $89,954 | $23.38 | -3,847 | 121,338 | 30 Jul 2026 | Direct |
| Gwenn Hansen | NRIX | Common Stock | Options Exercise | 8.85% | 10,180 | 125,185 | 30 Jul 2026 | Direct | ||
| Gwenn Hansen | NRIX | Restricted Stock Units | Options Exercise | -47.5% | -10,180 | 11,250 | 30 Jul 2026 | Direct | ||
| Christine Ring | NRIX | Common Stock | Sale | -44.8% | $259,366 | $23.56 | -11,008 | 13,579 | 02 Jul 2026 | Direct |
| Christine Ring | NRIX | Common Stock | Options Exercise | 81.1% | 11,008 | 24,587 | 02 Jul 2026 | Direct | ||
| Christine Ring | NRIX | Employee Stock Option (right to buy) | Options Exercise | -100% | -11,008 | 0 | 02 Jul 2026 | Direct | ||
| Gwenn Hansen | NRIX | Common Stock | Sale | -4.48% | $107,880 | $20.00 | -5,394 | 115,005 | 25 Jun 2026 | Direct |
| Christine Ring | NRIX | Common Stock | Sale | -68.1% | $580,506 | $20.06 | -28,935 | 13,579 | 25 Jun 2026 | Direct |
| Christine Ring | NRIX | Common Stock | Options Exercise | 213.1% | 28,935 | 42,514 | 25 Jun 2026 | Direct | ||
| Christine Ring | NRIX | Employee Stock Option (right to buy) | Options Exercise | -100% | -28,935 | 0 | 25 Jun 2026 | Direct | ||
| Christine Ring | NRIX | Common Stock | Sale | -37.5% | $135,253 | $16.60 | -8,148 | 13,579 | 02 Jun 2026 | Direct |
| Christine Ring | NRIX | Common Stock | Options Exercise | 18.7% | 3,422 | 21,727 | 02 Jun 2026 | Direct | ||
| Christine Ring | NRIX | Employee Stock Option (right to buy) | Options Exercise | -39.6% | -3,422 | 5,221 | 02 Jun 2026 | Direct | ||
| Paul M. Silva | NRIX | Director Stock Option (right to buy) | Award | 31,250 | 31,250 | 15 May 2026 | Direct | |||
| Edward C. Saltzman | NRIX | Director Stock Option (right to buy) | Award | 31,250 | 31,250 | 15 May 2026 | Direct | |||
| Judith A. Reinsdorf | NRIX | Director Stock Option (right to buy) | Award | 31,250 | 31,250 | 15 May 2026 | Direct | |||
| David L. Lacey | NRIX | Director Stock Option (right to buy) | Award | 31,250 | 31,250 | 15 May 2026 | Direct | |||
| Anil Kapur | NRIX | Director Stock Option (right to buy) | Award | 31,250 | 31,250 | 15 May 2026 | Direct | |||
| Roger D. Dansey | NRIX | Director Stock Option (right to buy) | Award | 31,250 | 31,250 | 15 May 2026 | Direct | |||
| Roy D. Baynes | NRIX | Director Stock Option (right to buy) | Award | 31,250 | 31,250 | 15 May 2026 | Direct | |||
| Julia P. Gregory | NRIX | Director Stock Option (right to buy) | Award | 31,250 | 31,250 | 15 May 2026 | Direct |
* marks a reported price that did not pass the local price check.